Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Cash from Financing Activities (2024 - 2025)

Pelthos Therapeutics has reported Cash from Financing Activities over the past 2 years, most recently at $18.0 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $18.0 million for Q4 2025, up 25126.39% from a year ago — trailing twelve months through Dec 2025 was $45.3 million (up 630.17% YoY), and the annual figure for FY2025 was $45.3 million, up 630.17%.
  • Cash from Financing Activities for Q4 2025 was $18.0 million at Pelthos Therapeutics, down from $26.7 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for PTHS hit a ceiling of $26.7 million in Q3 2025 and a floor of -$972015.0 in Q3 2024.